MD Anderson and Summit Therapeutics announce strategic collaboration to accelerate development of ivonescimab
University of Texas MD Anderson Cancer CenterMD Anderson and Summit Therapeutics announced a strategic five-year collaboration to accelerate the development of ivonescimab, a novel PD-1/VEGF bispecific antibody.